Review Article
Embryonic Signaling Pathways and Rhabdomyosarcoma: Contributions to Cancer Development and Opportunities for Therapeutic Targeting
Table 2
Clinical trials evaluating drugs that target Notch, WNT, or Hedgehog signaling pathways in children.
| ClinicalTrials.gov no. | Indication | Compound | Mechanism | Phase | Start date | Completion date | Sponsor/collaborator |
| Notch |
| NCT00100152 | Relapsed/refractory T cell ALL/lymphoma | MK0752 | Gamma-secretase inhibitor | I | Jul 2005 | Oct 2006 | Merck | NCT01088763 | Relapsed/refractory solid tumors, CNS tumors, lymphoma, T cell leukemia | RO4929097 | Gamma-secretase inhibitor | I/II | Mar 2010 | May 2011 | Children’s Oncology Group/NCI | NCT01236586 | Relapsed/refractory solid tumors, CNS tumors, lymphoma, T cell leukemia | RO4929097 | Gamma-secretase inhibitor | I/II | Oct 2010 | Apr 2011 | NCI/NIH CC |
| WNT |
| Hedgehog |
| NCT00822458 | Recurrent/refractory medulloblastoma | GDC-0049 | Smo small-molecule inhibitor | I | Jan 2009 | Jul 2011 | Pediatric brain tumor consortium/NCI | NCT01239316 | Recurrent/refractory medulloblastoma | GDC-0449 | Smo small-molecule inhibitor | II | Nov 2010 | Ongoing | Pediatric brain tumor consortium/NCI | NCT01125800 | Medulloblastoma, rhabdomyosarcoma, neuroblastoma, hepatoblastoma, high-grade glioma, astrocytoma | LDE225 | Smo small-molecule inhibitor | I | Feb 2011 | Ongoing | Novartis Pharmaceuticals |
|
|
Obtained from clinicaltrials.gov website January 8, 2012.
|